Myriad Genetics (MYGN), the U.S.-based molecular diagnostic company, employs a variety of proprietary technologies that allow doctors and their patients to understand the genetic origins of diseases and their respective treatment. While MYGN has been taking a heavy hit due to competition, and a lengthy lawsuit over its patenting practices, its excessive put options open interest is indicative of its slide coming to an end.
Myriad Genetics (MYGN), the U.S.-based molecular diagnostic company, employs a variety of proprietary technologies that allow doctors and their patients to understand the genetic origins of diseases and their respective treatment. While MYGN has been taking a heavy hit due to competition, and a lengthy lawsuit over its patenting practices, its excessive put options open interest is indicative of its slide coming to an end.
Share this Article
Recommended